Inogen Inc INGN
We take great care to ensure that the data presented and summarized in this overview for Inogen Inc is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding INGN
View all-
Camber Capital Management LP Boston, MA2MShares$18.9 Million0.62% of portfolio
-
Black Rock Inc. New York, NY1.63MShares$15.4 Million0.0% of portfolio
-
Brown Capital Management LLC Baltimore, MD1.56MShares$14.7 Million0.33% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.5MShares$14.2 Million0.0% of portfolio
-
Divisadero Street Capital Management, LP Miami, FL1.06MShares$9.99 Million1.38% of portfolio
-
Jpmorgan Chase & CO New York, NY896KShares$8.48 Million0.0% of portfolio
-
Ameriprise Financial Inc Minneapolis, MN844KShares$7.98 Million0.0% of portfolio
-
Fred Alger Management, LLC New York, NY713KShares$6.74 Million0.03% of portfolio
-
Bridgeway Capital Management, LLC Houston, TX603KShares$5.7 Million0.13% of portfolio
-
Acadian Asset Management LLC Boston, MA592KShares$5.6 Million0.02% of portfolio
Latest Institutional Activity in INGN
Top Purchases
Top Sells
About INGN
Inogen, Inc., a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The company offers Inogen One, a portable device that concentrate the air around the patient to provide a single source of supplemental oxygen; Inogen At Home stationary oxygen concentrators; Inogen Tidal Assist Ventilators, as well as related accessories. The company also rents its products directly to patients. Inogen, Inc. was incorporated in 2001 and is headquartered in Goleta, California.
Insider Transactions at INGN
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 05
2024
|
Heather D. Rider |
BUY
Grant, award, or other acquisition
|
Direct |
21,871
+27.52%
|
-
|
|
Jun 05
2024
|
Kevin M King |
BUY
Grant, award, or other acquisition
|
Direct |
21,871
+32.1%
|
-
|
|
Jun 05
2024
|
Glenn S Boehnlein |
BUY
Grant, award, or other acquisition
|
Direct |
21,871
+32.1%
|
-
|
|
Jun 05
2024
|
Elizabeth Mora |
BUY
Grant, award, or other acquisition
|
Direct |
21,871
+31.05%
|
-
|
|
Jun 05
2024
|
Mary Kay Ladone |
BUY
Grant, award, or other acquisition
|
Direct |
21,871
+32.1%
|
-
|
|
Jun 05
2024
|
Thomas A. West |
BUY
Grant, award, or other acquisition
|
Direct |
21,871
+34.97%
|
-
|
|
Jun 01
2024
|
Jason Somer EVP, Gen. Counsel & Secretary |
SELL
Payment of exercise price or tax liability
|
Direct |
339
-6.74%
|
$2,712
$8.3 P/Share
|
|
Jun 01
2024
|
Jason Somer EVP, Gen. Counsel & Secretary |
BUY
Exercise of conversion of derivative security
|
Direct |
577
+10.29%
|
-
|
|
May 10
2024
|
Jason Somer EVP, Gen. Counsel & Secretary |
SELL
Open market or private sale
|
Direct |
10,000
-69.19%
|
$80,000
$8.56 P/Share
|
|
May 01
2024
|
Stanislav Glezer EVP, R&D & Chief Med. Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
16,695
-34.25%
|
$116,865
$7.05 P/Share
|
|
May 01
2024
|
Stanislav Glezer EVP, R&D & Chief Med. Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
32,638
+40.1%
|
-
|
|
May 01
2024
|
Jason Somer EVP, Gen. Counsel & Secretary |
SELL
Payment of exercise price or tax liability
|
Direct |
11,312
-43.91%
|
$79,184
$7.05 P/Share
|
|
May 01
2024
|
Jason Somer EVP, Gen. Counsel & Secretary |
BUY
Exercise of conversion of derivative security
|
Direct |
19,276
+42.8%
|
-
|
|
Mar 01
2024
|
Jason Somer EVP, Gen. Counsel & Secretary |
SELL
Payment of exercise price or tax liability
|
Direct |
4,576
-41.36%
|
$32,032
$7.03 P/Share
|
|
Mar 01
2024
|
Jason Somer EVP, Gen. Counsel & Secretary |
BUY
Exercise of conversion of derivative security
|
Direct |
7,150
+39.26%
|
-
|
|
Mar 01
2024
|
Stanislav Glezer EVP, R&D & Chief Med. Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
7,623
-32.13%
|
$53,361
$7.03 P/Share
|
|
Mar 01
2024
|
Stanislav Glezer EVP, R&D & Chief Med. Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
13,914
+36.96%
|
-
|
|
Dec 01
2023
|
Stanislav Glezer EVP, R&D & Chief Med. Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,331
-19.19%
|
$11,655
$5.72 P/Share
|
|
Dec 01
2023
|
Stanislav Glezer EVP, R&D & Chief Med. Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,555
+27.27%
|
-
|
|
Dec 01
2023
|
Jason Somer EVP, Gen. Counsel & Secretary |
SELL
Payment of exercise price or tax liability
|
Direct |
286
-6.81%
|
$1,430
$5.72 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 131K shares |
|---|---|
| Exercise of conversion of derivative security | 78.7K shares |
| Payment of exercise price or tax liability | 43.2K shares |
|---|---|
| Open market or private sale | 10K shares |